151
For immunohistochemistry, tissue sections were incubated with primary antibody in 1% 152 goat or donkey serum/0.3% Triton X-100/PBS overnight, followed by incubation with secondary 7 antibody conjugated with Alexa Fluor 488, 568 or 647 (Molecular Probes), and coverslipped with 154 Vectashield (#101098-042) for confocal microscopy (LSM 510 & 720) . The following antibodies 155 were used:
156

Primary Antibodies Source & Catalogue Number Dilution
Chicken Anti-GFP Chemicon, AB16901 1:500
Goat Anti-SOX10 R&D Systems, AF2864 1:20
Guinea Pig Anti-ASCL1 Kim et al., 2008, TX518 1:1,000 -1:10,000
Mouse Anti-GFAP Sigma, G3893 1:500
Mouse Anti-MBP Calbiochem, NE1019 1:300
Mouse Anti-NEUN Chemicon, MAB377 1:1,000
Rabbit Anti-Ki67 Abcam, ab15580 1:500
Rabbit Anti-OLIG2 Millipore, AB9610 1:1,000
Rabbit Anti-SOX2 Millipore, AB5603 1:1,000
Rat Anti-PDGFR (APA5) BD Pharmingen, 558774 1:100 8 For RNA-seq experiments, the brain tumors were carefully dissected to enrich for tumor 168 tissues and total RNA was extracted using a Direct-zol RNA MiniPrep Kit (Zymo Research) . RNA 169 integrity number (RIN) for all tumors was determined to be between 8-10 using a Bioagilent
170
Analyzer. ChIP DNA and input DNA from PDX-GBMs and total RNAs from mouse brain tumors 171 were sent for library preparation and sequencing on an Illumina High-Seq 2000 at the UT 172 Southwestern Next Generation Sequencing Core.
173
To analyze ASCL1 ChIP-seq data, sequence reads were aligned to the human reference 174 genome (hg19) using bowtie2 (v.2.2.6) (Langmead & Salzberg, 2012) . Low-quality reads and 175 duplicate reads were removed from aligned files using "samtools view -bh-F 0 × 04 -q 10" (v1.2) 176 (Li, 2011) and "Picard MarkDuplicates.jar" (v. 1.131) commands (Picard 2018, Broad Institute,
177
GitHub repository). The ChIP-seq signal enriched regions were identified using the "findPeaks" 178 module available in HOMER software (v.4.7) (Heinz et al., 2010) . The ChIP-seq signal shown in 179 UCSC browser tracks are normalized read counts. De novo motif discovery and analysis were 180 performed using "findMotifsGenome" module available in HOMER software (v.4.7) . A 150 bp 181 region around the peak summit was used to identify the primary binding motif and other potential 182 DNA-binding co-Lanfactor motifs.
183
To analyze mouse tumor RNA-seq data, sequenced reads were aligned to the mouse 184 mm10 genome using TopHat 2.1.0 (Kim et al., 2013) . Default settings were used, with the 185 exception of -G, specifying assembly to the mm10 genome, --library-type fr -first strand, and -186 no-novel-juncs, which disregards noncanonical splice junctions when defining alignments. (Gangemi et al., 2009; Ligon et al., 2007; Lu et al., 2016; Park et al., 2017; Rheinbay et al., 2013;  240 Singh et al., 2017; Somasundaram et al., 2005) . However, the extent to which these factors are 
246
Quantification shows that each transcription factor occupied 74%, 81%, and 85% of tumor cells 247 counterstained with DAPI, respectively ( Figure 1N ). Co-localization analysis revealed that 48% of 248 ASCL1+ tumor cells were positive for the proliferation marker Ki67 ( Figure 1K -M,O), whereas over 249 90% of ASCL1+ cells were OLIG2+ and SOX2+ ( Figure 1O ), indicating that these three 250 transcription factors are co-expressed in the majority of the PDX-GBM cells in vivo.
251
We next sought to determine the expression level of ASCL1, OLIG2, and SOX2 across of more than one subtype, which we referred collectively to as mixed GBMs ( Figure S1 ). This
258
finding echoes previous reports demonstrating the presence of multiple GBM subtype identities 259 in different regions or cells of the same GBM tumors (Patel et al., 2014; Sottoriva et al., 2013) .
260
Expression of ASCL1, OLIG2, and SOX2 across these GBM subtypes showed that they were 261 highest in the proneural and classical subtypes, intermediate in the neural and mixed subtypes, 262 but were extremely low in the mesenchymal subtype, even in comparison to normal brain ( Figure   263 1P-R). Collectively, these findings illustrate that ASCL1, OLIG2, and SOX2 are co-expressed at for each PDX-GBM, was noticeably higher than background for the combined 13,457 peaks 280 called, indicating that the ASCL1 binding profile was similar in both PDX-GBMs ( Figure 2A , Table   281 S1).
282
To validate the quality and efficiency of our ChIP-seq, we next analyzed ASCL1 binding 
293
Interestingly, we found that SOX and FOXO motifs were also significantly enriched within ASCL1 294 binding peaks ( Figure 2C ), suggesting that ASCL1 may function in combination with these 295 transcription factor families to regulate gene expression in GBMs.
13
To identify putative-targets of ASCL1 in GBMs, we then used GREAT (McLean et al., 297 2010) to associate nearby genes that were upstream or downstream of the 13,457 ASCL1 binding 298 peaks. From this analysis, we uncovered a total of 8,791 genes (red oval, Figure 2D ). We 299 reasoned that if these genes are regulated by ASCL1 then they should also be expressed in a 300 manner correlated with ASCL1 expression in GBMs. By applying Spearman's rank-ordered 301 correlation (>0.4) to RNA-seq of the 164 TCGA GBM samples, we then identified the top 10% of 302 genes that showed a positive correlation with ASCL1 expression across these tumor samples.
303
We found 2,136 genes that are positively correlated with ASCL1 expression (green oval, Figure   304 2D). When we cross referenced these 2,136 genes with the 8,791 genes identified from the 305 ASCL1 ChIP-seq, there was an overlap of 1,106 genes, which we define as ASCL1 target genes 306 in GBM (yellow area, Figure 2D ). Supporting the validity of this approach, all ASCL1 canonical 307 targets examined were included in this 1,106 putative-target gene list ( Figure 2D , Table S2 ).
308
By evaluating the ASCL1 putative-target gene list, we uncovered a variety of genes that (Table S2 ). Strong ASCL1 binding peaks at the loci of some of these 322 genes in the PDX-GBMs lines are illustrated (asterisks, Figure 2E -H).
323
We next wanted to know how the expression of the 1,106 ASCL1 putative-target genes 324 sort across the various GBM subtypes using RNA-seq of the 164 primary GBMs. Heatmap and 325 dendrogram analysis revealed that, similar to ASCL1, the 1,106 putative-target genes were highly 326 expressed in the proneural and classical GBM subtypes, in the majority of neural and mixed GBM 327 subtypes, but was mostly absent in the mesenchymal GBM subtype ( Figure 2I ). In all, 109 of the 328 TCGA GBM samples were positive for the ASCL1 putative-target genes, while the remaining 55 329 samples express very little or low levels of the ASCL1 putative-targets.
330
To gain insights into the collective significance of the 1,106 ASCL1 putative targets, we 
341
Carcinoma, and Endometrial Cancer were also enriched for ASCL1 targets ( Figure 2J , Table S3 ).
342
Taken together, these findings suggest that ASCL1 is a transcriptional regulator at the epicenter 343 of multiple biological processes that are fundamental to cancer development. , 2011) . This implies that the ectopic GFAP found infiltrating the YFP+ tumor tissue in our model 378 may be reactive astrocytes rather than tumor cells themselves.
379
From P60-120, we found that 100% of Nf1;Tp53 CKO mice exhibited neurological symptoms 380 and tumors that had evolved into an expanded mass with high mitotic index and microvascular 381 proliferation resembling that of high grade gliomas ( Figure 4A,B) . We termed these Ascl1 WT tumor 382 mice (N=29, blue line), which exhibited a median survival of 102 days, while CreER-negative 383 littermate controls (N=19, green line) were tumor-free and healthy ( Figure 4P ). Over 90% of the 384 tumors were found in the cortex and/or striatum area, while a minority were also found in olfactory 385 bulb, diencephalon, midbrain, or cerebellum ( Figure 4O ). Similar to the early tumors and the PDX-
386
GBMs, ASCL1, OLIG2, and SOX2 were co-expressed in the tumor cells of these terminal tumors, 387 and many ASCL1+ tumor cells were also Ki67+ ( Figure 4C-J) . PDGFRa was also highly co-388 expressed by the ASCL1+ (Figure 4K ) and OLIG2+ (not shown) tumor cells, whereas GFAP and 389 to a lesser extent S100b and NEUN, although found in some parts of the tumor, did not overlap 390 significantly with SOX2 or ASCL1 ( Figure 4L-N) .
391
Overall, our findings illustrate that ASCL1, OLIG2, and SOX2 are co-expressed in tumor 392 cells of both early and terminal tumors of the glioma mouse model in vivo, and tumor cells maintain 393 a molecular identity reminiscent of that of OPCs.
395
Loss of ASCL1 decreases the proliferation of gliomas and increases the survival of tumor
bearing mice
Currently, the direct requirement of ASCL1 in brain tumor formation and progression from 398 low-grade gliomas to high-grade GBMs in vivo remains unknown. To address this, we 399 incorporated Ascl1 GFP knock-in (null) and Ascl1 Floxed alleles into the glioma mouse model to 400 generate Glast CreERT2 ;Ascl1 GFP/F ;Nf1 F/F ;Tp53 F/F and Glast CreERT2 ;Ascl1 F/F ;Nf1 F/F ;Tp53 F/F mice, 401 respectively, both of which when administered with tamoxifen at E14.5 will result in triple 402 conditional knock-out of Ascl1 along with Nf1 and Tp53 (Ascl1;Nf1;Tp53 CKO ). To control for the 403 possible effects of genetic background on glioma phenotype observed, we also generated 404 Glast CreERT2 ;Ascl1 GFP/+ ;Nf1 F/F ;Tp53 F/F and Glast CreERT2 ;Ascl1 F/+ ;Nf1 F/F ;Tp53 F/F mice in parallel for 405 comparison, both of which developed tumors that are still heterozygous for Ascl1 when induced 406 with tamoxifen, and are referred to as Ascl1 HET tumor mice.
407
Previous reports demonstrate that ASCL1 is essential for the proliferation of GBM cell 408 lines in vitro (Park et al., 2017; Rheinbay et al., 2013) . In contrast, in vivo we found that 409 Ascl1;Nf1;Tp53 CKO mice (hence forth referred to as Ascl1 CKO tumor mice, N=39) still developed 410 high-grade tumors that were phenotypically consistent with high grade gliomas ( Figure 5A ).
411
Furthermore, Ascl1 CKO tumor penetrance and location ( Figure 5L ,M) in the brain was similar to 412 the Ascl1 HET (not shown) and Ascl1 WT tumors ( Figure 4O ,P). We confirmed that ASCL1 was 413 indeed absent in Ascl1 CKO tumors. As illustrated for a Glast CreERT2 ;Ascl1 GFP/F ;Nf1 F/F ;Tp53 F/F mouse,
414
GFP driven by the endogenous Ascl1 locus marks precisely the tumor cells but ASCL1 was no 415 longer detected (Figure 5B,C) . Notably, OLIG2 and SOX2 ( Figure 5D ,E,J,K), which we identified 416 as ASCL1 target genes, were still expressed, indicating that expression of these two transcription 417 factors do not depend solely on ASCL1. Similarly, OPC markers such as PDGFR , the 418 chondroitin sulfate NG2, and SOX10 were still expressed in the Ascl1 CKO tumors (Figure 5D ,F,G).
419
As observed in Ascl1 WT tumors, GFAP did not co-colocalize extensively with GFP+ tumor cells, 420 despite being expressed in some regions of the tumor (Figure 5H,I) . Together, these findings 421 demonstrate that glial transcription factors and the OPC-like identity of the tumor cells are still 422 retained in the absence of ASCL1.
Notably, the Ascl1 CKO tumor mice survived longer compared to Ascl1 HET and Ascl1 WT tumor 424 mice. Specifically, while the Ascl1 HET tumor mice (N=34) died between P60-130, with a median 425 survival of 104 days, which is very similar to Ascl1 WT tumor mice (median survival of 102 days),
426
Ascl1 CKO tumor mice (N=39) died later between P90-180, with a median survival of around 122 427 days (compare red versus light and dark blue lines, Figure 5M ). This improvement in survival for 428 the Ascl1 CKO tumor mice also holds true even when analyzed by gender (not shown) and strongly 429 suggests that it was due to the loss of ASCL1.
430
To determine what may account for the improved survival of the Ascl1 CKO tumor mice, we To determine if the loss of ASCL1 altered the molecular profiles of the mouse glioma 446 tumors, we carefully isolated tumor tissues from Ascl1 WT (N=5) and Ascl1 CKO (N=5) tumor mice 447 for bulk RNA-seq analysis. RNA-seq tracks of the Ascl1 locus show that Exon 1 and 2 of the Ascl1 448 mRNA (containing the entire coding sequence), were completely absent in all Ascl1 CKO tumors 19 but were present in Ascl1 WT tumors ( Figure 6A ), confirming efficient deletion of the Ascl1 Floxed 450 allele. We first compared the transcriptomes of the Ascl1 WT and Ascl1 CKO tumors with 451 transcriptomes of CNS cell types, including OPCs, newly formed oligodendrocytes (NFO), mature 452 oligodendrocytes (MO), astrocytes (AS), neurons, and whole cortex (WC) (Zhang et al., 2014) . A 453 multidimensional scaling (MDS) plot shows that both the Ascl1 WT and Ascl1 CKO tumors cluster 454 together and away from the CNS cell types, and therefore are more similar to each other than to 455 neurons or any of the glial lineage cells ( Figure 6B ). When we further analyzed RNA-seq of 456 Ascl1 WT and Ascl1 CKO tumors using the top 50 signature genes for each CNS cell type, both tumor 457 types more closely resemble that of OPCs versus the other CNS cell types ( Figure 6C ). This 458 finding further supports the notion that OPCs, which are highly proliferative, may be the precursor 459 cell-of-origin for the glioma tumors in this model.
460
Finally, we sought to identify genes that are differentially expressed between Ascl1 WT and 461 Ascl1 CKO tumors. Analysis of ASCL1 canonical target genes revealed that Dll3, similar to Ascl1, 462 was significantly decreased, while Hes5 and Hes6 were lowered ( Figure 6D ), but Dll1, Notch1, 463 and Insm1 (not shown) were unchanged in Ascl1 CKO tumors. Interestingly, glial transcription 464 factors Nfia and Nfib, and several mitotic (Aurkb) and chromatin modifying (Hdac5) genes were 465 significantly decreased, whereas Olig1, Olig2, and cell cycle genes (Ccnd2, and Cdk4) were 466 modestly reduced in Ascl1 CKO tumors (Figure 6E,G) . In contrast, Sox genes were bidirectionally 467 affected by the loss of ASCL1. For instance, although Sox3 and Sox11 were decreased, Sox2 468 and Sox4 appeared upregulated in the Ascl1 CKO tumors (Figure 6F ). Heatmap and dendrogram 469 analysis of all 1,054 ASCL1 putative targets (converted from a list of 1,106 genes from human 470 GBMs, Table S3 ), revealed that there were as many genes being upregulated as there were 471 genes being downregulated by the loss of ASCL1 ( Figure 6H , Table S4 ). We also identified over 472 50 indirect targets of ASCL1 that were either upregulated or downregulated in the Ascl1 CKO tumors 473 ( Figure 6I , Table S5 ). Finally, in agreement with our earlier finding that tumor cell proliferation is 474 decreased in the absence of ASCL1, gene-set-enrichment analysis revealed that cell cycle related 475 20 genes were highly enriched in the down-regulated genes in the Ascl1 CKO tumors ( Figure 6J ). This 476 suggests that a decreased in cell-cycle related gene expression may contribute to the increase in 477 survival of the Ascl1 CKO tumor mice.
478
In summary, our findings highlight an in vivo role for ASCL1 in modulating the expression 479 of a variety of genes, including neurodevelopmental or glial transcription factors and cell cycle 480 genes, either directly or indirectly, that are crucial for the proliferation of GBM tumors in the brain.
482
DISCUSSION
483
We demonstrate in this study that ASCL1 is highly expressed in the majority of PDX-GBM 484 cells in vivo, with over 90% of ASCL1+ cells co-expressing OLIG2 and SOX2. Interestingly, in 485 addition to OLIG2 and SOX2, we find that expression of a variety of other genes encoding 486 transcription factors such as NFI, POU domain, Sal-like, SOX, as well as homeobox are also 487 highly correlated with ASCL1 expression in RNA-seq of primary GBMs (Table S2 ). This finding is 488 similar to that previously reported in GSCs from cultured GBM cell lines (Rheinbay et al., 2013;  489 Suva et al., 2014) . Accordingly, we find that these transcription factor encoding genes are not 490 only correlated with ASCL1 expression but are also targets of ASCL1 binding (Table S1 ). These 491 findings support a complex transcription factor interaction network in which the co-expression of 492 these transcription factors may be interdependent on each other, and this co-expression is 493 essential for regulating genes crucial for maintaining GSCs in an aberrant stem-like state of 494 dedifferentiation and proliferation. In agreement with this, it is not surprising that combinatorial 
498
ChIP-seq for ASCL1 has previously been performed for GBM cell lines in culture revealing 499 that ASCL1 directly interacts with Wnt signaling by binding to genes such as AXIN2, DKK1, FZD5,
500
LGR5, LRP5, TCF7 and TCF7L1. A model was proposed in which ASCL1 functions at least in 501 21 part by repressing an inhibitor of Wnt signaling, DKK1, resulting in increased signaling through 502 this pathway to maintain the tumorigenicity of GBM cells (Rheinbay et al., 2013) . Similarly, in this 503 study we find that all of the aforementioned genes as well as numerous other Wnt related genes 504 (GSK3B, LRP4, LRP6, TCF7L2) are directly bound by ASCL1 (Table S1 ). Additionally, expression 505 of many of these Wnt related genes is positively correlated with ASCL1 expression when analyzed 506 across RNA-seq of the 164 TCGA primary GBM samples, and Wnt Signaling and Pluripotency 507 was identified as one of the pathways significantly over-represented by the ASCL1 target genes 508 that we identified in this study ( Figure 2J , Table S2 ). Despite these findings, RNA-seq from mouse 509 Ascl1 CKO tumors revealed that expression of many of the Wnt related genes was unaffected by 510 the loss of ASCL1. Thus, although ASCL1 binds to and may contribute to the regulation of some 511 of these genes, particularly in an in vitro setting (Rheinbay et al., 2013) , expression of Wnt 512 pathway genes remains in GBMs in vivo in the absence of ASCL1. Consequently, the presence 513 of Wnt signaling may partly contribute to the formation of Ascl1 CKO tumors in the brain of the 514 glioma mouse model.
515
In addition to gliomas, ASCL1 is highly expressed in cancers with neuroendocrine 516 characteristics from multiple tissues including small cell lung carcinoma (SCLC), prostate cancer, 517 and thyroid medullary carcinoma (Chen, Kunnimalaiyaan, & Van Gompel, 2005; Rapa et al., 2013;  518 Zhang et al., 2018) . Previously, we reported that ASCL1 is required for tumor formation in a mouse 519 model of SCLC (Borromeo et al., 2016) . This finding reflects the requirement for ASCL1 in the 520 generation and survival of pulmonary neuroendocrine cells (PNECs), a presumptive cell-of-origin 521 for SCLC. In contrast, in this study we found that ASCL1 is not required for GBM formation in the 522 brain of the glioma mouse model, although disease progression is altered and the animals have , 2018; Nakatani et al., 2013; Parras et al., 2007; Vue et al., 2014) . Interestingly, in addition to 529 ASCL1 and OLIG2, transcription factors such as NFIA, SOX2, and SOX10 are also expressed in 530 OPCs. However, as OPCs differentiate to become mature oligodendrocytes, only OLIG2 and 531 SOX10 are maintained while ASCL1, NFIA, and SOX2 are down-regulated (Glasgow et al., 2014;  532 Laug, Glasgow, & Deneen, 2018; Nakatani et al., 2013) . This down-regulation suggests that the 533 co-expression of these transcription factors is important for maintaining OPCs in a progenitor-like 534 state, and the loss of just one of these factors does not completely abrogate tumor formation 535 following deletion of Nf1 and Tp53 because OPCs are still generated, and are thus susceptible to 536 being transformed into glioma. The direct roles of NFIA and OLIG2 in tumor development in 537 glioma mouse models were also previously tested. Similar to the findings for ASCL1, tumor 538 formation persisted in the absence of each of these transcription factors. Furthermore, despite 539 utilizing different approaches and driver mutations to induce tumor formation, the loss of NFIA or 540 OLIG2 was also accompanied by significant decreases in tumor cell proliferation resulting in an 541 increase in survival for their respective mouse models (Glasgow et al., 2017; Lu et al., 2016) .
542
Together, these studies illustrate potential redundant roles for neurodevelopmental or glial 543 transcription factors in driving GBM formation and progression in vivo in the brain, where the loss 544 of one factor is likely to be compensated by the remaining transcription factors.
545
Similar to our study here, deletion of Nf1, Tp53, along with or without Pten, was previously 546 shown to be fully penetrant in producing GBM tumors in the brain of mice (Alcantara Llaguno et 547 al., 2009; Alcantara Llaguno et al., 2015; Zhu et al., 2005) . More specifically, tumors were 548 successfully induced from neural stem cells in the SVZ of the lateral ventricles, including ASCL1+ 549 transiently amplifying progenitors, as well as OPCs. It was reported that two types of glioma 550 tumors were observed when Nf1 and Tp53 were deleted in the adult brain (Alcantara Llaguno et 551 al., 2015). Type 1 tumors, which are found in dorsal/anterior brain regions such as striatum, 552 hippocampus, and cortex, are highly infiltrative and aggressive. Type 2 tumors, on the other hand, 553 23 are found more in ventral/posterior brain regions such as the diencephalon and brainstem, and 554 exhibit well-defined boundaries. Based on gene expression, Type 1 tumors express high levels 555 of GFAP and are speculated to be derived from neural stem cells in the SVZ, whereas Type 2 556 tumors express high levels of OLIG2 and PDGFR , and likely to be derived from OPCs. Over 557 90% of the mouse GBM tumors that we observed in this study are found in the telencephalon, 558 predominantly in the cortex and striatum, suggesting that they may be similar to Type 1 tumors.
559
However, although GFAP expression is high in some of the tumors of our model, the majority of 560 GFAP expressing cells do not seem to co-localize with Cre-reporters such as YFP, which directly 561 mark the tumor cells. Instead, YFP colocalizes extensively with OLIG2 and PDGFR , indicating 562 that they are more similar to Type 2 tumors in terms of gene expression. This inconsistency likely 563 reflects our use of Glast CreERT2 to delete Nf1 and Tp53, which may target neural progenitors in the 564 SVZ as well as glial precursor cells outside of the SVZ, and the timing of tumor induction 565 embryonically in our model rather than in the adult brain.
566
In conclusion, the tumors induced in our mouse model are highly heterogenous based on 567 RNA-seq analysis, which is similar to that seen for human GBMs (Patel et al., 2014; Sottoriva et 568 al., 2013) . This heterogeneity is likely the result of different tumors being spontaneously derived 569 from different cell-of-origins in the various brain regions, and are thus exposed to different 570 microenvironments. Despite this heterogeneity, however, the loss of ASCL1 still significantly 571 delays tumor progression and resulted in a significant increase in survival for Ascl1 CKO tumor mice, 
